Drug candidate to rebuild stem cells given orphan drug status

fda-logo.jpg

The U.S. Food and Drug Administration has granted orphan drug status designation to Tarix Pharmaceuticals' TXA127, a drug target intended to be used in the engraftment of stem cell transplant patients with myelodysplastic syndromes.

TXA127 is designed to help patients rebuild their stem cells in the wake of a stem cell transplant without causing any additional bleeding or infection.

TXA127 is right now in Phase II clinical trials testing the drug's safety and efficacy in patients with Hodgkin's lymphoma, multiple myeloma, and non-Hodgkin's lymphoma.

By Ross Bonander

LymphomaInfo Social